---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-005425"
form_type: "8-K"
ticker: "BBOT"
cik: "0001869105"
company_name: "BridgeBio Oncology Therapeutics, Inc."
filed_at: "2026-01-07T23:59:59+00:00"
generated_at: "2026-05-16T11:25:05.110496+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# BBOT reports 65% ORR for BBO-8520, first panKRAS response in PDAC, no hyperglycemia with BBO-10203

## Summary
- BBO-8520 monotherapy: 65% ORR (11/17), 66% 6-month PFS, including one complete response; all 5 STK11/KEAP1 co-mutant patients achieved PR.
- BBO-8520 + pembrolizumab: all 8 evaluable patients had tumor reduction; 3/3 front-line and 2/5 prior KRAS G12C inhibitor patients achieved PR.
- BBO-11818 panKRAS inhibitor: first monotherapy PR in pancreatic ductal adenocarcinoma (44% tumor reduction); dose-proportional exposure covering G12D/G12V at 600 mg BID.
- BBO-10203 RAS:PI3Kα breaker: no hyperglycemia of any grade, no baseline HbA1c/glucose restrictions; 500 mg QD selected for expansion; combination studies initiated.
- Combination studies of BBO-8520, BBO-11818, and BBO-10203 with each other and with standard-of-care expected to open in H2 2026.

## SEC filing metadata
- accession: 0001193125-26-005425
- form_type: 8-K
- ticker: BBOT
- cik: 0001869105
- company_name: BridgeBio Oncology Therapeutics, Inc.
- filed_at: 2026-01-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1869105/000119312526005425/0001193125-26-005425-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1869105/000119312526005425/d941846d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-005425
- JSON: https://secwatch.observer/filing/0001193125-26-005425.json
- Plain text: https://secwatch.observer/filing/0001193125-26-005425.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.